Stoneridge Investment Partners LLC decreased its position in TherapeuticsMD Inc (NASDAQ:TXMD) by 58.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 195,743 shares of the company’s stock after selling 271,682 shares during the period. Stoneridge Investment Partners LLC’s holdings in TherapeuticsMD were worth $1,032,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TXMD. State Street Corp boosted its position in TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after buying an additional 253,237 shares during the period. Oppenheimer & Co. Inc. boosted its position in TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock worth $298,000 after buying an additional 20,148 shares during the period. Schwab Charles Investment Management Inc. boosted its position in TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after buying an additional 60,229 shares during the period. Geode Capital Management LLC boosted its position in TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock worth $9,213,000 after buying an additional 117,660 shares during the period. Finally, Vanguard Group Inc. boosted its position in TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after buying an additional 515,992 shares during the period.
TherapeuticsMD Inc (NASDAQ:TXMD) opened at 5.57 on Thursday. The firm’s market capitalization is $1.14 billion. The firm’s 50-day moving average price is $5.44 and its 200-day moving average price is $5.52. TherapeuticsMD Inc has a 1-year low of $3.50 and a 1-year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. TherapeuticsMD’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.11) EPS. On average, equities research analysts predict that TherapeuticsMD Inc will post ($0.44) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2796461/stoneridge-investment-partners-llc-reduces-stake-in-therapeuticsmd-inc-nasdaqtxmd.html.
A number of research analysts have commented on the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $10.00 price target on shares of TherapeuticsMD in a research note on Friday, July 21st. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Thursday. Deutsche Bank AG assumed coverage on TherapeuticsMD in a research note on Friday, July 21st. They set a “buy” rating and a $10.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price target on shares of TherapeuticsMD in a research note on Friday, July 21st. Finally, Cowen and Company restated an “outperform” rating and set a $13.00 price target on shares of TherapeuticsMD in a research note on Monday, July 17th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.14.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.